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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.05.004BACKGROUND: Thyroid cancer is the second most common malignancy among females at King Faisal Spe-
cialist Hospital and Research Centre (KFSH&RC) and in Saudi Arabia, accounting for about 11% of all newly
diagnosed female cancers in the country in 2008. Over the past several decades, an increasing incidence of thy-
roid cancer has been reported in the Kingdom of Saudi Arabia. There are no comprehensive clinical epidemi-
ological data for the trends of thyroid cancer incidence compared to the global incidence. This report reviews
the thyroid cancer incidence in KFSH&RC and compares that with Saudi Arabia, the Gulf region, North America
and globally from 2000 to 2010.
METHODS: Retrospective review of patients with thyroid cancer was carried out from 2000 to 2010, using the
hospital Tumor Registry program as per the American College of Surgeons standards. Trends and patterns of all
well-known prognostic factors were sub-stratified by age, stage and grade.
RESULTS: A total of 2292 patients with thyroid cancer were treated at KFSH&RC, Riyadh, Saudi Arabia, from
2000 to 2010. Thyroid cancer constitutes about 9% of all malignancies and 12% of all female malignancies at
KFSH&RC, which are significantly higher compared to the USA, where thyroid cancer represents only 2.9% of
all malignancies and 4.6% of all female malignancies. Papillary adenocarcinoma was the most common histo-
logical subtype followed by papillary carcinoma, follicular variant. Median age at diagnosis was 40 for females
and 44 years for males. Overall Age-Standardized Incidence Rate (ASR) was 4.4/100,000 (6.8 for female and
2/100,000 for males) in the Kingdom in 2008. Median age at diagnosis was 38 years and the highest incidence
was in the 30–39 year age group in KFSH&RC. About 48% of patients presented in the localized stage and 60%
underwent combined modality treatment consisting of surgery, radiation and hormonal therapy. There was sig-
nificantly increased incidence among females as compared to males. The age-adjusted thyroid cancer incidence
rates from 2000 to 2010 varied three-fold more for females than for males. Considerable geographical variations
were present in thyroid cancer incidence in Saudi Arabia.
CONCLUSION: Thyroid cancer incidence rates have increased exponentially between 2000 and 2010 and
there is significant geographical variation in the incidence of thyroid cancer throughout the Kingdom. Thyroid
cancer has become the second most common cancer among young Saudi women with a male to female ratio at
0.3:1. Rising incidence of thyroid cancer in Saudi Arabia may be due to the increased detection and diagnosis of
the thyroid cancers and not only an increase in the true occurrence of thyroid cancer. More studies are required
to determine this significant difference at the molecular level.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
riginal research reportThyroid cancer is the second most commonmalignancy among women in King FaisalSpecialist Hospital & Research Centre
(KFSH&RC). It encompasses 8.8% of all malignan-
cies and 12% of female malignant cancers. Thyroid
cancer is signiﬁcantly less common among males with
a male to female ratio of 0.3:1.1
According to the 2008 Saudi Cancer Registry re-
port, there were a total of 727 cases of thyroid can-
cers; 606 among Saudis and 121 among non-Saudis.
Among Saudis, thyroid cancer accounted for 6.8%
of all newly diagnosed cases that year. This cancer
was ranked the second most common cancer among
females, and thirteenth among males affecting 131
(21.6%) males and 475 (78.4%) females. The male
to female ratio was 28:100. The overall ASR was
4.4/100,000 (2/100,000 for males and 6.8/100,000
for females). The ﬁve regions with the highest ASR
were Tabuk (6/100,000), the Eastern Region (5.9/
100,000), Riyadh (5.8/100,000), Qassim (5.7/
100,000), and the Northern Region (4.9/100,000).
The age distribution of thyroid cancer differs from
most other cancers, with thyroid malignancies occur-
ring at an earlier age. The median age at diagnosis was
44 years among males and 40 years among females.
The most common histological type of thyroid cancer
was papillary adenocarcinoma.2
At the regional level, thyroid cancer is the ﬁfth
most common cancer in Gulf Cooperation Council
(GCC) countries. A total of 5587 cases (5.9%) were
diagnosed between 1998 and 2007. The overall
ASR was 1.8 and 5.9 per 100,000 for males and fe-
males respectively. Thyroid cancer has a signiﬁcantly
higher incident rate among females in all GCC coun-
tries and is the second most common malignancy
among women. Qatari women have the highest inci-
dence of thyroid cancer (ASR 10.9/100,000). Inci-
dence of thyroid cancer continues to incline in GCC
countries with a 24% increase in males and a 63% in-
crease among females over the ten year period.3
In the United States, thyroid cancer constitutes
2.9% of all cancer cases and 4.6% of all female malig-
nancies, making it the ﬁfth most common cancer
among females. In 2012, it was estimated that a total
of 56,460 new cases (77% among females and 17% in
males) and 1780 deaths will occur due to thyroid can-
cer. The incidence rate has been increasing signiﬁ-
cantly since the mid-1990s and has become the
fastest increasing cancer in males and females.4–6
In Europe, it was estimated that there will be
24,800 new cases of thyroid cancer and approximately
3890 deaths among women and 2103 among men due
to thyroid cancer in 2007.7 Worldwide, thyroid can-
INCIDENCE OF THYROID CANCER IN SAUDI ARABIA oHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013cer is the ninth most common cancer among females
with an estimated incidence of 163,968 new cases and
24,177 deaths among women in 2008. The global
ASR for thyroid cancer among females is 4.6/
100,000.8 (Figure 1).MATERIALS AND METHODS
A total of 2292 patients treated for thyroid cancer at
the KFSH&RC between 2000 and 2010 were in-
cluded in this review. The hospital tumor registry
data, maintained as per the American College of
Surgeons (ACOS) standards, were retrospectively
analyzed from 2000 to 2010. Only patients with his-
to-pathologically conﬁrmed thyroid cancers were in-
cluded in this study. All patients were staged
according to the SEER summary staging criteria.
Tumor grade was assessed from the pathology re-
ports and categorized as ‘well’, ‘moderate’ and ‘poorly
differentiated’, based upon the histological character-
istics, cellular atypia, and degree of differentiation.
Several prognostic factors were stratiﬁed and sub-
stratiﬁed by age and gender. The data analysis was
carried out using the SPSS statistical software
package.RESULTS
In the Kingdom of Saudi Arabia, thyroid cancer is the
second most frequent cancer among females after
breast cancer with a male to female ratio of 28:100,
with signiﬁcant prevalence among females. Thyroid
cancer patients treated at the KFSH&RC from
2000 to 2010 comprised 76.3% females and 23.7%
males.
Histopathology
At KFSH&RC, histopathological conﬁrmation re-
vealed 72% papillary adenocarcinoma and 13.6%
mixed papillary and follicular carcinoma, 2.1% papil-
lary microcarcinoma, 1.2% papillary carcinoma
columnar cell, and 0.7% papillary carcinoma encap-
sulated (Table 1). In comparison, most of the pa-
tients in Saudi Arabia were histopathologically
conﬁrmed papillary adenocarcinoma (58%), as per
the Saudi Cancer Registry, 2008 Cancer Incidence
Report.
Age
The highest incidence of thyroid cancer was between
30–39 years of age and the median age of thyroid
cancer patients was 38 years, as shown in Table 2.











Figure 1. Global incidence of thyroid cancer among females (courtesy of GLOBOCAN 2008, IARC, WHO).
Table 1. Histopathological distribution of thyroid cancers in KFSH&RC.
Pathology Total Females Males
n % n % n %
Papillary carcinoma 2063 90.01 1600 91.54 463 85.12
Follicular carcinoma 117 5.1 85 4.86 32 5.88
Follicular adenocarcinoma NOS 73 3.18 52 2.97 21 3.86
Oxyphilic adenocarcinoma 32 1.40 21 1.20 11 2.02
Follicular carcinoma minimal invasive 12 0.52 12 0.69 0 0
Medullary carcinoma NOS 52 2.27 28 1.6 24 4.41
Carcinoma anaplastic NOS 33 1.44 19 1.09 14 2.57
Others 27 1.18 16 0.92 11 2.02
Carcinoma NOS 8 0.35 4 0.23 4 0.74
Carcinoma undifferentiated NOS 3 0.13 1 0.06 2 0.37
Neoplasm malignant 2 0.09 2 0.11 0 0.00
Non encapsulated sclerosing carcinoma 2 0.09 1 0.06 1 0.18
Adenocarcinoma NOS 1 0.04 0 0.00 1 0.18
All others 11 0.48 8 0.46 3 0.55
Total 2292 100% 1748 100% 544 100%
60
original research report INCIDENCE OF THYROID CANCER IN SAUDI ARABIAdiagnosis contributed a substantial proportion of thy-
roid cancers to about 50% of all thyroid cancer cases.
The highest incidence of thyroid cancer was in the
30–39 year age group (Figure 3). In comparison,
the average age group for developing any cancer in
Saudi Arabia was 45–59 years. However, thyroid can-
cer has struck males and females at a signiﬁcantly
younger age group: between the ages of 35 and
45 years. The median age for thyroid cancer patients
in Saudi Arabia is 40 years among females and
44 years among males (Figure 2).Stage
All thyroid cancers were staged according to the
International Union Against Cancer (UICC), TNM
staging and American Joint Commission on Cancer
(AJCC) system. Most patients in Saudi Arabia pre-
sented in the localized/regional stage of thyroid can-
cer as shown in Figure 4. In KFSH&RC, between
2000 and 2010, the majority of the thyroid cancer pa-
tients (48%) were diagnosed in localized stage, as
shown in Table 3. However, from 1975 to 2010,
about 40.5% of thyroid cancers were diagnosed inHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
Table 2. Thyroid cancer distribution by age groups in KFSH&RC.













Figure 2. Age Specific Incidence Rate (AIR) for thyroid cancer in Saudi A
Figure 3. Age distribution for thyroid cancer at KFSH&RC, 2011 (courtesy
Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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localized stage and 39.7% were diagnosed in regional
stage (Figure 5).
Treatment
About 60% patients received multimodality treatment
consisting of surgery, combined with radiation and
hormonal therapy. A combination of surgery and hor-
monal therapy was administered to about 22.8% and
surgery alone was given to 7% of the patients. Surgery
and radiation therapy combination was given to 5.3%
of the patients compared to radiotherapy alone that
was given to only 0.8% of the patients. A summary
of treatment is presented in Table 4.DISCUSSION
Thyroid cancer constitutes more than 90% of tumors
of the endocrine system. There are several subtypes of
thyroid cancers based upon histological characteris-
tics, molecular and clinical features. Prognosis of thy-rabia (courtesy of Saudi Cancer Registry, 2008).
of KFSH&RC Tumor Registry Annual Report, 2011).
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Figure 5. SEER summary stage distribution for thyroid cancer in KFSH&RC, 1975–2010 (courtesy of KFSH&RC Tumor Registry Annual Report, 2010).
Figure 4. Stage distribution of thyroid cancer in Saudi Arabia (courtesy of Saudi Cancer Registry, 2008).




Reg dir exta 175 7.6
Reg LNb 477 20.8
Reg LN & Extc 274 12.0
Distant metsd 174 7.6
Unknown 86 3.8
Total 2292 100
aRegional direct extension.bRegional lymph nodes.cRegional lymph nodes and direct extension.
dMetastases.
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original research report INCIDENCE OF THYROID CANCER IN SAUDI ARABIAroid cancer varies widely from a ﬁve year survival rate
of >98% for differentiated thyroid cancer to a four
month median survival for anaplastic thyroid cancer.
High vascularity, oncogenic mutations in the RAS,
RAF and MEK pathway and oncogenicity by RET
gene have resulted in multitarget inhibitors for various
histological subtypes of thyroid cancers.9 Thyroid
cancers in the Middle East are unique on a molecular
level, particularly an increased ampliﬁcation of the
PIK3CA gene.10
The incidence of thyroid cancer has increased sig-
niﬁcantly around the world. The rate increased from
3.6/100,000 in 1973 to 8.7/100,000 in 2002, without
any change in the mortality rate.11 There were dra-
matic changes in the thyroid cancer incidence rates
between 1973 and 1977 and between 1998 and
2002 from countries all around the globe.12 Thyroid
cancer contributed 8.8% of all cancers diagnosed at
KFSH&RC during 2010, which was signiﬁcantly
higher than the proportion in the United States
(2.9%). The rate for females was at least three times
as high as those for males and patients 30–39 years
of age at diagnosis who contributed the largest pro-
portion of cases, with 55% of all the cases below the
age of 39 years. Papillary adenocarcinomas accounted
for 72 of all thyroid cancers.
There is global difference in the incidence of thy-
roid cancer. In the US, thyroid cancer is the ﬁfth most
common cancer among women, while in Saudi Ara-
bia, it is the second most common cancer among wo-
men. Risk factors include being female, history of
goiter, family history of thyroid cancer, radiation
exposure, certain genetic diseases, low dietary intakeof iodine, overweight, environmental radiation, in-
creased imaging or high levels of leptin in the
body.13–16
Thyroid cancer is a signiﬁcant health care burden
for the Kingdom of Saudi Arabia, prevalent in every
region and encompassing each age group in the coun-
try. Exacerbated by western lifestyles and rapid urban-
ization due to major economic development in the
country, the health care burden will continue to in-
crease exponentially as social and cultural norms
change. With no screening guidelines or well-deﬁned
screening method for early detection of thyroid cancer
in the Kingdom, patients are generally detected in the
later stages of the disease.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
Table 4. Definitive treatment administered for thyroid cancers in
KFSH&RC between 2000 and 2010.














INCIDENCE OF THYROID CANCER IN SAUDI ARABIA original research reportThere are several possible explanations as to why
thyroid cancer is signiﬁcantly more frequent among
women in Saudi Arabia compared to other countries
around the world. The ﬁrst possibility is iodine deﬁ-
ciency. It has been noticed that thyroid cancer is less
frequently diagnosed in the US than in countries
where iodine is not part of the diet. Iodine deﬁciency
and endemic goiters are associated with increased risk
of follicular thyroid cancer. Despite the lack of sub-
stantial data on iodine deﬁciency in the Arabian Pen-
insula, the existing research shows that Saudi Arabia
has a slight amount of iodine deﬁciency, particularly
in the south.17–18
Radiation exposure, especially during childhood, is
a signiﬁcant risk factor for differentiated papillary car-
cinoma;19 radioactive fallout, depleted uranium, nu-
clear testing and the Chernobyl disaster are some of
the well-known risk factors for thyroid cancer.20–23
According to the Saudi Cancer Registry data, the
highest incidence of thyroid cancer and leukemia is
in the Tabuk and Eastern Province regions indicating
a probable correlation with depleted uranium (DU)
exposure in this region resulting from Iraq war. Fam-
ily history is another possibility especially for papillary
thyroid cancer and the joint incidence of papillary thy-
roid cancer and colon cancer among families affected
by familial adenomatous polyposis.24 New and rare
BRAF mutations in malignant and non-malignantHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013thyroid tumors in cases of T599dup and K601E seem
to confer certain risk for progressive TC.25 There is a
correlation of family history with TC in the Saudi
population.26 The incidence of follicular thyroid can-
cer and breast cancer is higher among patients with
family history of Cowden disease.27 The RET
proto-oncogens may be altered or changed, causing
medullary thyroid cancer from the C-Cells. This gene
may be passed from parent to child genetically.28
These genetic mutations may lead to the development
of thyroid cancers.
Excessive food intake leads to excessive leptin
throughout the body.29–30 The amount of leptin,
one of the molecules causing obesity, also plays a role
in this increased frequency of thyroid cancer. Leptin
may also help predict prognosis of thyroid cancer.
Leptin receptor expression may be a useful marker
in predicting the stages of thyroid tumors in the Mid-
dle East region and help guide treatment and follow
up.31 Obesity in Saudi Arabia is high and remains
an emerging public health issue.32–36 About 68.3%
of the Saudi Arabian population are overweight.37
Thyroid cancer rates in Saudi Arabia are well
above those of industrialized nations and are expected
to rise even higher due to population growth, com-
pounded by the possible implications of an aging pop-
ulation, rapidly changing lifestyles including dietary
habits, iodine deﬁciency, obesity, lack of exercise,
and urbanization.CONCLUSION
Thyroid cancer is the second most common malig-
nancy among women in Saudi Arabia, with an expo-
nential increase in the incidence rates over the last few
years. The exact cause of this changing trend is un-
known. However, several risk factors have been iden-
tiﬁed including iodine deﬁciency, family history,
obesity, radiation exposure and high leptin levels.
The escalating incidence of thyroid cancers in the
Kingdom of Saudi Arabia may also be due to in-
creased early detection and diagnosis of thyroid can-
cers for signiﬁcant expansion of health care sector
and outreach programs and not necessarily due to a
true increase in the occurrence of thyroid cancers.
The predominance of thyroid cancer in the Kingdom
and the Gulf region necessitates prioritization at na-
tional and regional levels. Further clinical epidemio-
logical research is needed to determine successful
strategies for increasing awareness, screening, early
detection, diagnosis and management in Saudi Arabia
with unique cultural, racial and ethnic makeup as
compared to the West. More studies are required to63
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determine the etiology, environmental factors and lo-
cal characteristics of the disease in the Kingdom to
determine the signiﬁcance of the changing trends at
molecular and genetic levels. This report is the ﬁrst
comprehensive evaluation on thyroid cancer from
King Faisal Specialist Hospital & Research Centre
and the Saudi Cancer Registry, looking into the
increasing incidence, trends and patterns of thyroidcancer as a reference for deﬁning future public health
initiatives in cancer control in Saudi Arabia.CONFLICT OF INTEREST STATEMENT
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